Dexcom vs Resmed (DXCM vs RMD)
Side by side from their SEC filings: revenue, margins, growth, returns and valuation, plus short interest, insider activity and institutional ownership.
Resmed is the larger company by revenue ($5.7B vs $4.7B). Dexcom carries the larger market value ($34.0B vs $33.4B). Dexcom has grown revenue faster over the last 4 fiscal years (+90.4% cumulative vs +58.0%). Resmed runs the higher operating margin (33.4% vs 19.6%). Resmed trades at the lower trailing P/E (22.2x vs 35.6x).
About Dexcom
Dexcom Inc is a medical device company that designs, develops, and sells continuous glucose monitoring systems for diabetes and metabolic health management. Its main products include the Dexcom G7 and G7 15 Day systems, which provide real-time glucose readings and alerts to patients, caregivers, and clinicians. The company serves people with diabetes, including those using insulin, as well as adults with prediabetes and Type 2 diabetes who do not use insulin.
About Resmed
ResMed Inc develops and sells products and software for sleep and breathing health, including treatments for obstructive sleep apnea (OSA). The company serves healthcare providers, sleep clinics, and patients by offering devices and cloud-based business management software for residential care. ResMed focuses on innovation to compete in a market with evolving technology and alternative therapies.
Head to head (DXCM FY2025 vs RMD FY2026)
| Metric | DXCMFY2025 | RMDFY2026 |
|---|---|---|
| Revenue | $4.66B | $5.65B |
| Revenue growth (YoY) | 15.6% | 9.9% |
| Gross margin | 60.1% | 61.1% |
| Operating margin | 19.6% | 33.4% |
| Net margin | 17.9% | 26.9% |
| Net income | $836.3M | $1.52B |
| Diluted EPS | $2.09 | $10.43 |
| FCF margin | 23.1% | 29.2% |
| ROE | 30.5% | 23.1% |
| Long-term debt / equity | — | 0.06× |
| Market cap | $34.02B | $33.37B |
| P/E | 35.6× | 22.2× |
Fundamentals are from each company’s SEC filings (DXCM FY2025, RMD FY2026). ROE is net income over fiscal-year-end equity; long-term debt / equity counts non-current term debt only. P/E and market cap are derived from stored market prices, last retrieved on a rolling basis and typically within the past week.
Five-year trend (as reported)
| DXCM by fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $2.45B | $2.91B | $3.62B | $4.03B | $4.66B |
| Net income | $216.9M | $341.2M | $541.5M | $576.2M | $836.3M |
| Operating margin | 10.9% | 13.4% | 16.5% | 14.9% | 19.6% |
| RMD by fiscal year | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| Revenue | $3.58B | $4.22B | $4.69B | $5.15B | $5.65B |
| Net income | $779.4M | $897.6M | $1.02B | $1.40B | $1.52B |
| Operating margin | 28.0% | 26.8% | 28.2% | 32.7% | 33.4% |
Dexcom and Resmed use different fiscal calendars (DXCM's FY2025 ended 2025-12-31, RMD's FY2026 ended 2026-06-30), so their fiscal years are shown separately rather than forced into one timeline.
Peer standing
Where each company ranks among the 88 medical device companies, on the same scale. Each figure is ranked only against peers that report it. Percentiles describe position in the distribution, not a rating.
| Metric | DXCM | RMD |
|---|---|---|
| Gross margin | 60.1%42nd percentile of 77 | 61.1%43rd percentile of 77 |
| Operating margin | 19.6%92nd percentile of 80 | 33.4%Highest of 80 |
| Net margin | 17.9%90th percentile of 81 | 26.9%98th percentile of 81 |
| FCF margin | 23.1%93rd percentile of 74 | 29.2%96th percentile of 74 |
| Revenue growth (YoY) | +15.6%57th percentile of 87 | +9.9%38th percentile of 87 |
| ROE | 30.5%95th percentile of 79 | 23.1%91st percentile of 79 |
| P/E | 35.6×68th percentile of 32 | 22.2×35th percentile of 32 |
| Short interest (days to cover) | 2.94d43rd percentile of 88 | 7.41d85th percentile of 88 |
Short interest
| FINRA settlement data | DXCM | RMD |
|---|---|---|
| Shares sold short | 16.5M | 12.8M |
| Change vs prior settlement | -5.8% | -18.4% |
| Days to cover | 2.94 | 7.41 |
| As of settlement | 2026-08-14 | 2026-08-14 |
Source: FINRA Consolidated Short Interest. FINRA is the owner and source of the FINRA-supplied data; republishing or redistributing it is not permitted. Not presented as a percentage of float. No FINRA endorsement of this product is implied.
Insider activity (last 90 days)
| Form 4 activity (codes P/S) | DXCM | RMD |
|---|---|---|
| Buys | 0 | 0 |
| Sells | 15 ($8.1M) | 4 ($4.9M) |
Non-derivative purchases (code P) and sales (code S) reported on SEC Form 4, which may be open-market or private (grants, exercises and tax withholding excluded). For context, about 15% of covered companies saw any reported insider purchase (code P) in a 90-day window.
Held by the same investors
8 tracked 13F managers hold both Dexcom and Resmed as of their latest quarterly filings: AQR Capital Management, Bridgewater Associates, Citadel Advisors, D. E. Shaw, Gotham Asset Management, Millennium Management, Renaissance Technologies, Two Sigma Investments. See which superinvestors hold your own portfolio with the smart money checker.
Go deeper
BDX vs DXCMBSX vs DXCMDXCM vs MDLNDXCM vs MMMDXCM vs SYKDXCM vs WSTAll medical device stocks →All comparisons →
Track DXCM and RMD
Get an alert when either company files something material, see which superinvestors own them, and ask their filings a question with cited answers.
Start monitoring freeIncludes one free filing-grounded research answer. Or check your whole portfolio, no account needed.
Data sourced from SEC EDGAR. Figures are as-reported and may be unaudited or restated; verify against the source filings before relying on them. Comparisons are descriptive (higher or lower on a reported figure), not a rating or a recommendation. Informational only. Not investment advice.